ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients with Cancer
Previous Study | Return to List | Next Study

Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01148407
Recruitment Status : Unknown
Verified April 2011 by University of Vermont.
Recruitment status was:  Recruiting
First Posted : June 22, 2010
Last Update Posted : April 22, 2011
Sponsor:
Information provided by:
University of Vermont

Brief Summary:
Blood samples on persons with cancer will be sampled for angiogenic, metastatic and coagulation proteins.

Condition or disease
Cancer

Study Type : Observational
Estimated Enrollment : 30 participants
Official Title: Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer
Study Start Date : June 2010
Estimated Primary Completion Date : August 2012
Estimated Study Completion Date : August 2013



Biospecimen Retention:   Samples Without DNA
plasma, serum and platelet activated blood samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with a malignancy diagnosis.
Criteria

Inclusion Criteria:

  • Patients with a diagnosis of malignancy

Exclusion Criteria:

  • Patients taking aspirin, NSAIDs, warfarin or platelet inhibitor therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01148407


Contacts
Contact: Chris E Holmes, MD, PhD 802-656-0302 ceholmes@uvm.edu

Locations
United States, Vermont
University of Vermont/Fletcher Allen Health Care Recruiting
Burlington, Vermont, United States, 05401
Contact: Barbara Kelly       bkelly@uvm.edu   
Principal Investigator: Chris E Holmes, MD PhD         
Sponsors and Collaborators
University of Vermont
Investigators
Principal Investigator: Chris E Holmes, MD PhD University of Vermont

Responsible Party: Chris E. Holmes, MD, PhD, University of Vermont
ClinicalTrials.gov Identifier: NCT01148407     History of Changes
Other Study ID Numbers: VCC 0806
First Posted: June 22, 2010    Key Record Dates
Last Update Posted: April 22, 2011
Last Verified: April 2011

Keywords provided by University of Vermont:
breast cancer
platelets
metastatic cancer
malignancy